

BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B

An introduction to BioArctic Pareto

September 3, 2020

Gunilla Osswald, PhD, CEO




Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BioArctic – a unique Swedish biopharma company

Improving life for patients with central nervous system disorders



High unmet need for disease-modifying treatments for Alzheimer's and Parkinson's diseases creates **large commercial opportunity**



World-class research and development driven organization with basis in founder's breakthrough discoveries and fruitful collaborations with leading **academic researchers** and **pharma companies** generating and developing **innovative projects**




Attractive and well-balanced project portfolio with projects from discovery through Phase 3 and combination of both proprietary projects with substantial marketing and out-licensing potential and partnered projects generating income




Well-financed with BSEK >1 (MUSD >100) in cash, **net profitable** during the last seven years and **valuable collaboration agreements** totaling BSEK 9.6 (BUSD ~1) plus royalties

We focus on disease modifying agents and diagnostics/biomarkers for neurodegenerative diseases

Neurodegenerative disease therapy TODAY



Neurodegenerative disease therapy TOMORROW



Significant unmet medical need to be addressed by disease modifying agents and reliable diagnostics/biomarkers

Long-standing and extensive partnerships – an important part of our business model

Alzheimer's disease

Partner track record





Discovered and developed world's best-selling medicine for symptoms in Alzheimer's



Industry-leading pipeline in dementia area

Collaboration and license



- BioArctic retains rights to BAN2401 in other indications and option to market in the Nordics

Sources: Eisai, AbbVie and BioArctic corporate information

Parkinson's disease

Partner track record



World's all-time best-selling medicine (BUSD 20)





10 different indications in immunology

Approved product for symptoms associated with Parkinson's disease



Collaboration and license



- AbbVie global rights to alpha-synuclein portfolio for all indications

**Why should we succeed where
many others have failed?**



BAN2401: potential disease modifying antibody for Alzheimer's disease with positive Phase 2b results now in Phase 3

High unmet medical need

No existing disease-modifying treatment



**IN 20
YEARS**
doubling

TODAY

>30 million
people with Alzheimer's

BAN2401 unique profile

Unique and targeted binding profile

- Highly selective for toxic forms of misfolded Abeta (oligomers/protofibrils)


Unique clinical fingerprint

- Rapid onset of clinical effect
- Consistent effects
- No titration required due to low frequency of ARIA-E

BAN2401 has positive Phase 2b results

- **Large trial:** 856 early Alzheimer's patients
- **Consistent effects** on clinical outcomes, imaging and neurodegenerative biomarkers
- **Effect increase over time**
- **Good safety profile**

Broad BAN2401 clinical program – driven by BioArctic’s partner Eisai



ABBV-0805: potential disease modifying antibody for Parkinson's disease with strong preclinical results now in Phase 1

High unmet medical need

No existing disease-modifying treatment



Younger patient group, still at working age

TODAY

>6 million¹ people with Parkinson's

Unique profile

Unique and targeted binding profile


- Highly selective for toxic forms of misfolded alpha-synuclein (oligomers/protofibrils)

Built on genetic and pathology rationale


- Alpha-synuclein mutations lead to Parkinson's
- Alpha-synuclein oligomers/protofibrils are elevated in Parkinson's

Preclinical proof of concept

Reduction of neurotoxic alpha-synuclein oligomers/protofibrils



Delays disease progression and increases lifespan




1) Dorsey and Bloem, JAMA Neurology 2018;75:9-10

Continued progress in collaboration with AbbVie on alpha-synuclein

Collaboration highlights

- ABBV-0805 targeting disease modification in Parkinson's disease
- Potential to expand to earlier stage Parkinson's disease patients and other diseases where alpha-synuclein plays a role
- AbbVie is responsible for clinical development
- BioArctic is responsible for delivering follow-up antibodies in the continued collaboration with AbbVie

ABBV-0805 advancing in clinical trials



Recent highlights

BAN2401

- Recruitment of early Alzheimer patients for Clarity AD confirmatory Phase 3 study ongoing
 - Swedish clinics now included in Phase 3 study
- Phase 2b open label extension study data presented at AAIC
 - Rapid reduction of amyloid in the brain (already at 3 months)
 - Consistent low level of adverse event ARIA-E (<10%)
- Phase 3 study in preclinical AD, AHEAD 3-45, initiated

Discovery stage programs

- New collaboration initiated with University of Oslo regarding ApoE

ABBV-0805

- Recruitment to Phase 1 MAD study canceled. Detailed plan to accelerate the project into Phase 2 currently being prepared by AbbVie



Upcoming news flow

Alzheimer's disease



BAN2401 (Eisai)

- To present data at international congresses
- Phase 3 confirmatory study results 2022
- Phase 2b open label extension study results
- Phase 3 prevention study results

Discovery stage programs

- Advance into preclinical development

Parkinson's disease




ABBV-0805 (AbbVie)

- Complete Phase 1 and start Phase 2
- Publications on the collaboration

Discovery stage projects

- Development in AbbVie collaboration


Other CNS disorders



Neurodegeneration research

- New project development
- New indications and new targets

Blood-brain barrier technology



Blood-brain barrier technology platform

- Continue development of platform

Diagnostics



Diagnostics

- Continue development of imaging and biochemical biomarkers

BioArctic: With Patients in Mind

Built on science



Projects in focus

	Project	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
ALZHEIMER'S DISEASE	BAN2401	Eisai, Biogen ¹	[Progress bar]				
	BAN2401 back-up	Eisai	[Progress bar]				
	AD1801		[Progress bar]				
	AD1502		[Progress bar]				
	AD1503		[Progress bar]				
PARKINSON'S DISEASE	AD2803		[Progress bar]				
	ABBV-0805 ²	AbbVie	[Progress bar]				
	PD1601	AbbVie	[Progress bar]				
OTHER CNS DISORDERS	PD1602	AbbVie	[Progress bar]				
	BAN2401 Down's syndrome ³ Traumatic brain injury		[Progress bar]				
BLOOD-BRAIN BARRIER TECHNOLOGY	ND3014		[Progress bar]				
	BBB technology platform		[Progress bar]				
DIAGNOSTICS	Imaging and biochemical biomarkers – Alzheimer's disease		[Progress bar]				
	Imaging and biochemical biomarkers – Parkinson's disease	AbbVie	[Progress bar]				

Value-driven leadership





Questions?